3-(4-chlorobenzol)propyl bromide

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-(4-chlorobenzol)propyl bromide
• 英文别名: 1-(1-Bromopropyl)-2-chlorobenzene
• 化学式: C₉H₁₀BrCl
• 分子量: 233.535
• InChiKey: LQRYDYCPRGMDJV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  0

反应信息

• 作为反应物：
  描述：

  3-(4-chlorobenzol)propyl bromide 、 4-苯氨基-哌啶 在 K2CO3 作用下， 以 丙酮 为溶剂， 生成 4-benzamido-1-[4-(p-chlorophenyl)-4-oxobutyl]piperidine
  参考文献：
  名称：

  DNA encoding a human melanin concentrating hormone receptor (MCH1) and uses thereof

  摘要：

  该发明提供了编码人类MCH1受体的孤立核酸，纯化的人类MCH1受体，含有编码人类MCH1受体的孤立核酸的载体，含有这种载体的细胞，针对人类MCH1受体的抗体，用于检测编码人类MCH1受体的核酸探针，与编码人类MCH1受体的核酸的独特序列互补的反义寡核苷酸，表达编码正常或突变人类MCH1受体的转基因非人类动物，分离人类MCH1受体的方法，治疗与人类MCH1受体活性相关的异常的方法，以及确定化合物与哺乳动物MCH1受体结合的方法。该发明还提供了一种治疗患有尿失禁的受试者的方法，包括向受试者投予足以治疗受试者尿失禁的MCH1拮抗剂。

  公开号：

  US20040038855A1

文献信息

• Aromatic amine derivatives
  申请人：Synaptic Pharmaceutical Corporation

  公开号：US05508306A1

  公开（公告）日：1996-04-16

  This invention relates to novel aromatic amine compounds having the structure: ##STR1## where each W, Z.sup.1 and Z.sup.2 is independently H, C.sub.1 -C.sub.6 alkyl, C.sub.1 -C.sub.6 alkoxy, OH, F, Cl, Br, I, NO.sub.2, CN, SO.sub.2 NHR.sup.3, NR.sup.4.sub.2, CONR.sup.3.sub.2, COR.sup.5 ; where each R.sup.1 and R.sup.2 is independently H, C.sub.1 -C.sub.6 straight or branched chain alkyl or phenyl; where each X and Y is independently CH.sub.2, NR.sup.4, S, S.dbd.O, SO.sub.2 ; where n is 0, 1 or 2; where each p and q is independently 1 or 2; where R.sup.3 is H, C.sub.1 -C.sub.6 straight or branched chain alkyl or phenyl; where R.sup.4 is H, C.sub.1 -C.sub.6 straight or branched chain alkyl or COR.sup.3 ; and where R.sup.5 is H, C.sub.1 -C.sub.6 straight or branched chain alkyl or phenyl, C.sub.1 -C.sub.6 straight or branched chain alkoxy or OH. In addition the invention includes using such compounds for the treatment of benign prostatic hyperplasia, lowering intraocular pressure and inhibiting cholesterol synthesis.

  这项发明涉及具有以下结构的新型芳香胺化合物：其中每个W，Z.sup.1和Z.sup.2独立地为H，C.sub.1 -C.sub.6烷基，C.sub.1 -C.sub.6烷氧基，OH，F，Cl，Br，I，NO.sub.2，CN，SO.sub.2NHR.sup.3，NR.sup.4.sub.2，CONR.sup.3.sub.2，COR.sup.5；其中每个R.sup.1和R.sup.2独立地为H，C.sub.1 -C.sub.6直链或支链烷基或苯基；其中每个X和Y独立地为CH.sub.2，NR.sup.4，S，S.dbd.O，SO.sub.2；其中n为0、1或2；其中每个p和q独立地为1或2；其中R.sup.3为H，C.sub.1 -C.sub.6直链或支链烷基或苯基；其中R.sup.4为H，C.sub.1 -C.sub.6直链或支链烷基或COR.sup.3；其中R.sup.5为H，C.sub.1 -C.sub.6直链或支链烷基或苯基，C.sub.1 -C.sub.6直链或支链烷氧基或OH。此外，该发明还包括使用这些化合物治疗良性前列腺增生、降低眼内压和抑制胆固醇合成。
• DNA endoding human alpha 1 adrenergic receptors
  申请人：Synaptic Pharmaceutical Corporation

  公开号：US05861309A1

  公开（公告）日：1999-01-19

  This invention provides an isolated nucleic acid, vectors, transformed mammalian cells and non-human transgenic animals that encode and express normal or mutant alpha 1a, alpha 1b and alpha 1c adrenergic receptor genes. This invention also provides a protein, and an antibody directed to the protein and pharmaceutical compounds related to alpha 1a, alpha 1b and alpha 1c adrenergic receptors. This invention provides nucleic acid probes, and antisense oligonucleotides complementary to alpha 1a, alpha 1b and alpha 1c adrenergic receptor genes. This invention further provides methods for determining ligand binding, detecting expression, drug screening, and treatments for alleviating abnormalities associated with human alpha 1a, alpha 1b and alpha 1c adrenergic receptors.

  这项发明提供了编码和表达正常或突变的α1a、α1b和α1c肾上腺素受体基因的孤立核酸、载体、转化的哺乳动物细胞和非人类转基因动物。这项发明还提供了一种蛋白质，以及针对该蛋白质的抗体和与α1a、α1b和α1c肾上腺素受体相关的药物化合物。这项发明提供了与α1a、α1b和α1c肾上腺素受体基因互补的核酸探针和反义寡核苷酸。此外，这项发明还提供了测定配体结合、检测表达、药物筛选以及治疗与人类α1a、α1b和α1c肾上腺素受体相关异常的方法。
• Use of .alpha..sub.1C specific compounds to treat benign prostatic
  申请人：Synaptic Pharmaceutical Corporation

  公开号：US05403847A1

  公开（公告）日：1995-04-04

  A method of treating benign prostatic hyperplasia in a subject which comprises administering to the subject a therapeutically effective amount of a compound which binds to a human .alpha..sub.1C adrenergic receptor with a binding affinity greater than ten-fold higher than the binding affinity with which the compound binds to a human .alpha..sub.1A adrenergic receptor, a human .alpha..sub.1B adrenergic receptor, and a human histamine H.sub.1 receptor, and, binds to a human .alpha..sub.2 adrenergic receptor with a binding affinity which is greater than ten-fold lower than the binding affinity with which the compound binds to such .alpha..sub.1C adrenergic receptor. Compounds meeting these criteria are provided.

  一种治疗良性前列腺增生的方法，包括向患者投与一种与人类α1C肾上腺素受体结合的化合物的治疗有效量，其结合亲和力比其与人类α1A肾上腺素受体、人类α1B肾上腺素受体和人类组胺H1受体结合的亲和力高出十倍以上，并且与人类α2肾上腺素受体结合的亲和力比其与该α1C肾上腺素受体结合的亲和力低出十倍以上。提供符合这些标准的化合物。
• .alpha..sub.1C specific compounds to treat benign prostatic hyperplasia
  申请人：Synaptic Pharmaceutical Corporation

  公开号：US05990128A1

  公开（公告）日：1999-11-23

  This invention provides a method of treating benign prostatic hyperplasia in a subject which comprises administering to the subject a therapeutically effective amount of an .alpha..sub.1C antagonist which (a) binds to a human .alpha..sub.1C adrenergic receptor with a binding affinity greater than 100-fold higher than the binding affinity with which the .alpha..sub.1C antagonist binds to a human .alpha..sub.1A adrenergic receptor, a human .alpha..sub.1B adrenergic receptor, and a human histamine H.sub.1 receptor; and (b) binds to a human .alpha..sub.2 adrenergic receptor with a binding affinity which is greater than 100-fold lower than the binding affinity with which the .alpha..sub.1C antagonist binds to such .alpha..sub.1C adrenergic receptor. The invention further provides a method of inhibiting contraction of a prostate tissue which comprises contacting the prostate tissue with an effective contraction-inhibiting amount of an .alpha..sub.1C antagonist which (a) binds to a human .alpha..sub.1C adrenergic receptor with a binding affinity greater than 100-fold higher than the binding affinity with which the .alpha..sub.1C antagonist binds to a human .alpha..sub.1A adrenergic receptor, a human .alpha..sub.1B adrenergic receptor, and a human histamine H.sub.1 receptor; and (b) binds to a human .alpha..sub.2 adrenergic receptor with a binding affinity which is greater than 100-fold lower than the binding affinity with which the .alpha..sub.1C antagonist binds to such .alpha..sub.1C adrenergic receptor.

  该发明提供了一种治疗良性前列腺增生的方法，该方法包括向受试者施用治疗有效量的α1C受体拮抗剂，该拮抗剂（a）与人类α1C肾上腺素受体结合的亲和力比其与人类α1A肾上腺素受体、人类α1B肾上腺素受体和人类组织胺H1受体结合的亲和力高100倍以上；以及（b）与人类α2肾上腺素受体结合的亲和力比其与该α1C肾上腺素受体结合的亲和力低100倍以上。该发明还提供了一种抑制前列腺组织收缩的方法，该方法包括将前列腺组织与有效的抑制收缩量的α1C受体拮抗剂接触，该拮抗剂（a）与人类α1C肾上腺素受体结合的亲和力比其与人类α1A肾上腺素受体、人类α1B肾上腺素受体和人类组织胺H1受体结合的亲和力高100倍以上；以及（b）与人类α2肾上腺素受体结合的亲和力比其与该α1C肾上腺素受体结合的亲和力低100倍以上。
• Use of alpha-1C specific compounds to treat benign prostatic hyperplasia
  申请人：Synaptic Pharmaceutical Corporation

  公开号：US06015819A1

  公开（公告）日：2000-01-18

  A method of treating benign prostatic hyperplasia in a subject which comprises administering to the subject a therapeutically effective amount of a compound which binds to a human .alpha..sub.1C adrenergic receptor with a binding affinity greater than ten-fold higher than the binding affinity with which the compound binds to a human .alpha..sub.1A adrenergic receptor, a human .alpha..sub.1B adrenergic receptor, and a human histamine H.sub.1 receptor, and, binds to a human .alpha..sub.2 adrenergic receptor with a binding affinity which is greater than ten-fold lower than the binding affinity with which the compound binds to such .alpha..sub.1C adrenergic receptor. Compounds meeting these criteria are provided.

  一种治疗良性前列腺增生的方法，包括向受试者投予与人类α1C肾上腺素受体结合的化合物的治疗有效量，其结合亲和力比其与人类α1A肾上腺素受体、人类α1B肾上腺素受体和人类组胺H1受体结合的亲和力高出十倍以上，并且与人类α2肾上腺素受体结合的亲和力比其与该α1C肾上腺素受体结合的亲和力低出十倍以上。提供符合这些标准的化合物。